在减少肾病患者的血压和肾脏风险方面,新的药物巴克斯德罗斯特显示前景良好。 New drug baxdrostat shows promise in reducing blood pressure and kidney risks in kidney disease patients.

一种新的药物,即巴克斯德罗斯特,显示有望降低慢性肾病患者的高血压。 A new drug, baxdrostat, shows promise in lowering high blood pressure in patients with chronic kidney disease. 第二阶段试验发现,它减少了5%的静脉血压,将肾脏风险标记减少了55%。 The Phase 2 trial found it reduced systolic blood pressure by 5% and decreased a kidney risk marker by 55%. 它虽然有效,但导致一些病人的钾含量很高。 While effective, it caused high potassium levels in some patients. 该药物的成功可以改善那些患有无法控制的血压和肾病的人的长期健康结果。 The drug's success could improve long-term health outcomes for those with uncontrolled blood pressure and kidney disease.